Clinical trials: CBD
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Parkinson Disease
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.
- Trial name
- NCT01533077
- Testing
- BIA 9-1067, Sinemet® 100/25 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169453
- Testing
- BIA 9-1067, Sinemet® CR 100/25
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Healthy Volunteers
Dose-finding Pharmacokinetic Study in Healthy Males
This is a phase I PK study in healthy males.
- Trial name
- COMDOS1 (NCT03055936)
- Testing
- Levodopa, Carbidopa, ODM-104
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Cannabis Use Disorder
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use…
- Trial name
- CBD (NCT03102918)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Prevention
RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims
Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA.
- Trial name
- RCT (NCT06800066)
- Testing
- Purchase Behavior - (Non-CBD ads), Purchase Behavior - (CBD ads)
- Where
- United States
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Opioid Withdrawal, Opioid Craving
Oral Cannabidiol for Opioid Withdrawal
This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal.
- Conditions
- Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
- Trial name
- NCT04238754
- Testing
- Epidiolex
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Pain, Cannabis
Enhancing Medication-based Analgesia in Humans- STUDY 2
This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid cannabidiol (CBD; Epidiolex) would enhance analgesia, subjective reports, and…
- Conditions
- Pain, Cannabis, Opioid Use
- Trial name
- NCT04036968
- Testing
- Within-subject test of blinded study medications
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Memory
The Effect of Cannabidiol in Learning and Memory of Adults
The main objectives of this study were to test if a singular dose of Cannabidiol (1) enhances the learning and memory of healthy human subjects, (2) test if Cannabidiol has negative effects on Retroactive and Proactive…
- Trial name
- NCT06074172
- Testing
- Cannabidiol (246mg press pill)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Absorption; Chemicals
Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
Cannabidiol (CBD) has been approved as a treatment for rare childhood epilepsies and could be an effective treatment for psychotic disorders, anxiety disorders and addictions.
- Trial name
- CLIP (NCT05032807)
- Testing
- Standard formulation, Novel formulation
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- King's College London
Pain
Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
The purpose of this double-blind, placebo-controlled study is to determine the analgesic effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have intoxicating effects.
- Trial name
- NCT02751359
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Metabolism, Liver Function
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
According to a recent consumer poll, over 20 million Americans regularly use cannabidiol (CBD). Moreover, 64 million Americans (over 25% of the population) report trying CBD at least once within the previous 2 years.
- Conditions
- Metabolism, Liver Function, Pharmacokinetics
- Trial name
- NCT04971837
- Testing
- Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Parkinson Disease, Multiple System Atrophy
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
An experimental drug called L-DOPS increases production in the body of a messenger chemical called norepinephrine. Cells in the brain that make norepinephrine are often gone in Parkinson disease.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
- Trial name
- NCT00547911
- Testing
- Droxidopa, Carbidopa, Entacapone
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics
- Trial name
- NCT01533116
- Testing
- BIA 9-1067, levodopa/carbidopa, levodopa/benserazide
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD)
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg…
- Trial name
- NCT02170376
- Testing
- BIA 9-1067, Entacapone, Levodopa/carbidopa
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Muscle Injury, Recovery
Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury
We aim to determine the efficacy of a controlled short-term trial of CBD ingestion for reducing symptomatic response and facilitating recovery following induced muscle injury.
- Conditions
- Muscle Injury, Recovery, Pain Relief
- Trial name
- NCT04586712
- Testing
- Active CBD
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Florida
Parkinson's Disease (PD)
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a…
- Trial name
- NCT02169414
- Testing
- BIA 9-1067 5 mg, BIA 9-1067 25 mg, levodopa/carbidopa 100/25
- Where
- France
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
CBD, Transplant Complication
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant…
- Conditions
- CBD, Transplant Complication, Kidney Disease, Chronic
- Trial name
- NCT05490511
- Testing
- Tacrolimus single dose, Epidiolex single dose, Epidiolex steady-state and tacrolimus single dose
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Indiana University
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.